Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

Other

Istituto Superiore Di Sanita

Sciclone Pharmaceuticals, Inc.

Sciclone Pharmaceuticals International, Ltd.

Consiglio Nazionale Delle Ricerche

Università Degli Studi Di Firenze

Mimetech S.r.l.

Sciclone Pharmaceuticals International (Sg) Pte. Ltd.

Instituto Superiore Di Sanita

Minerva Patents S.a.

Montemurno, Concetta Antonia

First - Societa' a Responsabilita' Limitata Con Socio Unico

Rasi, Guido

Sinibaldi, Paola

Enrico Garaci

Luigina Romani

Francesco Bistoni

Guido Rasi

Antonio Guarna

Antonio Cassone

Antonello Mai

Mauro Magnani

Fiorenzo Refosco

Umberto Benatti

Anna Teresa Palamara

Paolo Di Francesco

Maria Gabriella Santoro

Flavia De Bernardis

Giuliano Elia

Andrea Savarino

Antonio Rossi

Vito M Fazio

Andrea Trabocchi

Luigia Rossi

Corrado Spadafora

Federico Cozzolino

Gerald Schumann

Enrico Millo

Maria Torcia

Carla Amici

Ilaria Sciamanna

Chiara De Luca

Monica Rinaldi

Paola Sinibaldi

Paola Sinibaldi-Vallebona

Fiorella Guadagni

Giorgio Brandi

Marina Lusic

Angelo Michele Palmieri

Marina Ziche

Vincenzo De Filippis

Francesco Stanisci

Mario Leonardo Granito

Mario Pazzagli

Maria Squeo

Concetta Antonia Montemurno

Vito Michele Fazio

Frederico Cozzolino

The present invention concerns Thymosin alpha 1 (Tα1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

Thymosin alpha 1 for use in treatment of cystic fibrosis

The present invention concerns Thymosin alpha 1 (T&#x3b1;1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

The present invention concerns Thymosin alpha 1 for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

The present disclosure relates to a monoclonal antibody specifically binding to human Long Interspersed Element-1 ORF2 encoded protein (L1-ORF2p) obtained from hybridoma chA1, and derivatives and uses thereof, including for prediction of response of cancer patients to NNRTI treatments. It also relates to a method for early detection of cell transformation in pre-neoplastic tissues of a human subject, comprising detecting in cells of a pre-neoplastic tissue sample from said subject the expression of L1-ORF2p, wherein the expression of L1-ORF2p indicates the presence of cell transformation in said pre-neoplastic tissues. It also relates to a method for detecting progression of colon adenoma in a human subject suffering from colon adenoma, based on detection of an increase of L1-ORF2p expression.

Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject

The invention relates to novel, Frizzled-like, immunogenic peptides, useful for the stimulation of an immune response against various cancer types, particularly colon rectal carcinoma.

Anti tumoral immunogenic peptides and vaccine thereof

Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a 'chain reaction' is sparked. This 'chain reaction' induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.

Treatment of retroviral reservoirs exploiting oxidative stress

The present invention refers to 3-aza-bicyclo [3.2.1] octane derivatives of general formula (I) their preparation, use and pharmaceutical compositions useful in the treatment of pathologies associated with microbial pathogens expressing aspartylprotease activity.

Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases

The use of resveratrol is described fir the preparation of a medicament for the treatment of influenza. Said medicament exerts itself in therapeutic activity through inhibition of viral replication.

Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections

A method for treating a human infected withby using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection byin an immuno-compromised host being treated with a bone marrow transplantation.

[object Object]

It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.

Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection

It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin.

Use of thymosin alpha 1 for the treatment of immunological diseases

The present invention refers to pharmaceutical preparations including as active compounds 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) and/or their dimers of general formula (II) and (III) acting as agonists of human neurotrophines. Therefore, such compounds of formula (I), (II) and (III) are useful for treatment of diseases in which the neurotrophine functions are involved in defect, particularly of Nerve Growth Factor (NGF), such as neurodegenerative diseases of central nervous system (CNS), acquired immunodeficiency due to a reduced NGF biodisponibility, or morbous conditions in which the stimulus of neoangiogenesis process is convenient.

Pharmaceutical compositions for the treatment of diseases related to neurotrophines

The invention relates to 2-cyclopenten-1-one as an inducer of the heat shock protein HSP70 by activating the heat shock transcription factor HSF, and selectively inducing the transcription and translation of HSP70 in human cells. In particular, since a cytoprotective role of HSP70 during viral infection was previously shown, the invention refers to 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives as inducers of HSP70 with antiviral activity. Treatment with 2-cyclopenten-1-one and its pharmaceutically acceptable derivatives causes a dose-dependent reduction of infectious virus yield during infection with vesicular stomatitis virus. The block of virus replication is due to inhibition of viral protein synthesis, associated with HSP70 synthesis.

2-cyclopenten-1-one as an inducer of HSP70

Growing community of inventors

Rome, Italy

Enrico Garaci